Be consistent: Skipping doses or stopping early can reduce effectiveness, leading to more costs in the long run
In hundreds of preclinical studies, BPC-157 has demonstrated the ability to accelerate healing in tendons, ligaments, muscle, bone, and the gastrointestinal mucosa
Pharmacokinetically, BPC-157 has a relatively short plasma half-life estimated at 10-15 minutes when administered parenterally, though its tissue-level effects persist far longer due to receptor-level interactions and growth factor cascading
Eur J Cancer
Real people, REAL RESULTS
they have also reported strange rashes, increased fatigue, depressed moods, and vision problems